British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults

What this platform has drawn from it — 6 claims

• The BSG guideline states that the selection of treatment modality in hepatocellular carcinoma depends as much on the underlying liver function and degree of portal hypertension as on the oncological stage of the tumour, as well as the patient's performance status. Treatment of hepatocellular carcinoma, introduction, p15
  read on Hepatocellular carcinoma
• The BSG guideline states that underlying liver disease and dysfunction has a significant impact on the chosen treatment, and may limit life expectancy more than the cancer. Staging of hepatocellular carcinoma, opening paragraph, p15
  held in the ledger, not rendered on any page
• The BSG guideline states that in patients with decompensated cirrhosis, treatment options for hepatocellular carcinoma apart from liver transplantation are severely restricted, whereas in patients with compensated liver disease multiple treatment options are potentially available. Treatment of hepatocellular carcinoma, introduction, p15
  read on Hepatocellular carcinoma
• The BSG guideline explains that the TNM staging system is inadequate in hepatocellular carcinoma because liver function is not considered, which is a key factor in defining both prognosis and treatment. Staging of hepatocellular carcinoma, paragraph on the TNM system, p15
  read on Hepatocellular carcinoma
• The BSG guideline states that assessment for resection of hepatocellular carcinoma in a cirrhotic liver is a multiparametric evaluation considering liver function linked to severity of portal hypertension, extent of hepatectomy, volume of the future liver remnant, and the patient's comorbidity profile and performance status. Recommendations: surgical resection, second bullet, p16 (also executive summary, p2)
  read on Hepatocellular carcinoma
• The BSG guideline records that NICE has defined Child-Pugh A and performance status 0 to 1 as eligibility criteria for NHS-funded systemic therapy in hepatocellular carcinoma. Recommendations: systemic therapy, general considerations
  read on Hepatocellular carcinoma